Eli Lilly’s Mounjaro Injection Could Generate $13B in Sales for Weight Loss Treatment

Trending News 🌧️

Eli Lilly’s Mounjaro injection could generate $13B in sales for weight loss treatment, according to Citi analyst Andrew Baum. Baum raised his peak Mounjaro forecast to more than $25B from $15B due to conversations with physicians and payers. The once weekly injection is approved for diabetes, but Lilly is eying Mounjaro as a weight-loss treatment which would greatly increase revenue. He added if upcoming data from Alzheimer’s candidates lecanemab from Eisai and gantenerumab from Roche is not strong, it would provide an opportunity to add to positions. Do you think this will affect ELI LILLY AND($NYSE:LLY) market and earnings in the long term? Yes, this will affect ELI LILLY AND market and earnings in the long term.

Market Price

On Thursday, ELI LILLY AND stock opened at $320.6 and closed at $323.1, up by 1.3% from prior closing price of 318.9. It is designed for people who are overweight or obese, and who have not been able to lose weight through diet and exercise alone. The company is already working on another weight loss drug, which is a pill that can be taken once a day.

VI Analysis

Eli Lilly and Company’s fundamentals reflect its long term potential. The company’s financials are solid, with a strong balance sheet and plenty of cash on hand. However, there are some potential risks to the business. One is the company’s dependence on a small number of blockbuster drugs. If any of these drugs face serious competition or lose patent protection, it could have a significant impact on the company’s bottom line. Another risk is the potential for regulatory changes that could impact the company’s ability to market its drugs. Overall, though, Eli Lilly and Company looks like a solid long-term investment.

For more details please visit Risk Rating.

Summary

If you’re looking for a big pharma stock to buy, Eli Lilly is a great option. Lilly’s stock has already been on the rise in recent months, as investors have started to anticipate the potential success of Mounjaro. Of course, there are always risks with any stock, and Lilly is no exception. The company is facing some generic competition for its blockbuster diabetes drug Trulicity, and its antidepressant Cymbalta will soon go off patent. However, Lilly’s strong portfolio of other products should help offset any potential sales losses from these drugs. Overall, Lilly looks like a solid pick for investors looking for exposure to the healthcare sector. The company’s promising new obesity drug could be a big winner, and its strong portfolio of other products gives it some downside protection.